glycyrrhizic acid has been researched along with Disease Exacerbation in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giardullo, P; Mancuso, M; Palone, F; Pasquali, E; Stronati, L; Vitali, R | 1 |
| Akuta, N; Arase, Y; Fukushima, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Lin, CC; Wang, PH | 1 |
| Patrick, L | 1 |
| Brouwer, JT; Hop, WC; Niesters, HG; Schalm, SW; van Rossum, TG; Vulto, AG | 1 |
| Harada, H; Kamitsukasa, H; Kojima, H; Murai, S; Tokita, H; Yagura, M | 1 |
1 review(s) available for glycyrrhizic acid and Disease Exacerbation
| Article | Year |
|---|---|
Hepatitis C: epidemiology and review of complementary/alternative medicine treatments.
Topics: Antioxidants; Antiviral Agents; Catechin; Complementary Therapies; Disease Progression; Glycyrrhizic Acid; Hepacivirus; Hepatitis C; Humans; Phytosterols; Plant Extracts; Ribavirin; Silymarin | 1999 |
1 trial(s) available for glycyrrhizic acid and Disease Exacerbation
| Article | Year |
|---|---|
Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycyrrhizic Acid; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Liver Function Tests; Male; Middle Aged | 1999 |
4 other study(ies) available for glycyrrhizic acid and Disease Exacerbation
| Article | Year |
|---|---|
Low Dose of Dipotassium Glycyrrhizate Counteracts Atherosclerosis Progression in Apoe-/- Female Mice.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Disease Models, Animal; Disease Progression; Female; Glycyrrhizic Acid; HMGB1 Protein; Inflammation Mediators; Lipids; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Sex Factors | 2019 |
Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anticarcinogenic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Glycyrrhizic Acid; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Middle Aged; Young Adult | 2014 |
Intravenous glycyrrhizin improved serum transaminases rapidly in a chronic hepatitis B patient with acute exacerbation.
Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents; Disease Progression; Glycyrrhizic Acid; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Transaminases | 2015 |
Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Disease Progression; Drugs, Chinese Herbal; Female; Glycyrrhizic Acid; Hepatitis C; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Peptide Fragments; Procollagen; Retrospective Studies; RNA, Viral; Ursodeoxycholic Acid | 2000 |